LISATA THERAPEUTICS INC (LSTA)

US1280583022 - Common Stock

2.77  -0.04 (-1.6%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LSTA. LSTA was compared to 586 industry peers in the Biotechnology industry. LSTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LSTA has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LSTA has reported negative net income.
In the past year LSTA has reported a negative cash flow from operations.
In the past 5 years LSTA always reported negative net income.
In the past 5 years LSTA always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of LSTA (-38.11%) is better than 62.39% of its industry peers.
Looking at the Return On Equity, with a value of -43.29%, LSTA is in the better half of the industry, outperforming 71.62% of the companies in the same industry.
Industry RankSector Rank
ROA -38.11%
ROE -43.29%
ROIC N/A
ROA(3y)-46.9%
ROA(5y)-46.91%
ROE(3y)-51.49%
ROE(5y)-54.52%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

LSTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

LSTA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LSTA has more shares outstanding
There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -11.92, we must say that LSTA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of LSTA (-11.92) is worse than 81.54% of its industry peers.
There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.92
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

LSTA has a Current Ratio of 8.18. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LSTA (8.18) is better than 69.91% of its industry peers.
LSTA has a Quick Ratio of 8.18. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.18, LSTA is doing good in the industry, outperforming 70.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.18
Quick Ratio 8.18

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.76% over the past year.
EPS 1Y (TTM)77.76%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q15.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, LSTA will show a small growth in Earnings Per Share. The EPS will grow by 6.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.77%
EPS Next 2Y-2.93%
EPS Next 3Y10.13%
EPS Next 5Y6.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSTA. In the last year negative earnings were reported.
Also next year LSTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.93%
EPS Next 3Y10.13%

More info and screens

0

5. Dividend

5.1 Amount

LSTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LISATA THERAPEUTICS INC

NASDAQ:LSTA (5/17/2024, 7:11:27 PM)

2.77

-0.04 (-1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap23.02M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.11%
ROE -43.29%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 8.18
Quick Ratio 8.18
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)77.76%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-21.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y